Sodium salicylate protects against rotenone-induced Parkinsonism in rats

Synapse

Volumn 67, Issue 8, 2013, Pages 502-514

  Madathil, Sindhu K ^a,b   Karuppagounder, Saravanan S ^a,c   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b UNIVERSITY OF KENTUCKY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antioxidant enzymes; Benzyl hydroxylation; Dopaminergic neuronal loss; Glutathione recovery; Unilateral rotational behavior

Indexed keywords

DOPAMINE; GLUTATHIONE DISULFIDE; NEUROPROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SALICYLATE SODIUM; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; ENZYME ACTIVITY; MALE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

AMPHETAMINE; ANIMALS; APOMORPHINE; CORPUS STRIATUM; CYCLOOXYGENASE INHIBITORS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; GLUTATHIONE; HYDROXYL RADICAL; MALE; NEURONS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SODIUM SALICYLATE; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; UNCOUPLING AGENTS;

EID: 84879556282     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21658     Document Type: Article

References (60)

1. Asanuma M, Miyazaki I. 2006. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: Possible involvement of quinone formation. Expert Rev Neurother 6:1313-1325.
2. Aubin NO, Curet A, Deffois C, Carter C. 1998. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642.
3. Betarbet R, Sherer TB, MacKenzie G, Osuna MG, Pavanov VA, Greenamyre TJ. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci 3:1301-1306.
4. Bornebroek M, de Lau LM, Haag MD, Koudstaal PJ, Hofman A, Stricker BH, Breteler MM. 2007. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 28:193-196.
5. Brigelius R, Muckel C, Akerboom TP, Sies H. 1983. Identification and quantitation of glutathione in hepatic protein mixed disulfides and its relationship to glutathione disulfide. Biochem Pharmacol 32:2529-2534.
6. Cao W, Carney JM, Duchon A, Floyd RA, Chevion M. 1988. Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neurosci Lett 26:233-238.
7. Carrasco E, Werner P. 2002. Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP(+): Protection by acetylsalicylic acid aspirin. Parkinsonism Relat Disord 8:407-411.
8. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. 2005. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58:963-967.
9. Chiueh CC, Wu RM, Mohanakumar KP, Sternberger LM, Krishna G, Obata T, Murphy DL. 1994. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann N Y Acad Sci 17:25-36.
10. Choi WS, Palmiter RD, Xia Z. 2011. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol 192:873-882.
11. Etminan M, Carleton BC, Samii A. 2008. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: A retrospective cohort study. J Clin Neurosci 15:576-577.
12. Ferger B, Spratt C, Teismann P, Seitz G, Kuschinsky K. 1998. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 360:155-163.
13. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH. 1999. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 360:256-261.
14. Floyd RA, Henderson R, Watson JJ, Wong PK. 1986. Use of salicylate with high pressure liquid chromatography and electrochemical detection (LCED) as a sensitive measure of hydroxyl free radicals in adriamycin treated rats. J Free Radic Biol Med 2:13-18.
15. Floyd RA, Watson JJ, Wong PK. 1984. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J Biochem Biophys Methods 10:221-235.
16. Gagne JJ, Power MC. 2010. Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology 74:995-1002.
17. Gao X, Chen H, Schwarzschild MA, Ascherio A. 2011. Use of ibuprofen and risk of Parkinson disease. Neurology 76:863-869.
18. Gören B, Mimbay Z, Bilici N, Zarifoǧlu M, Oǧul E, Korfali E. 2009. Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model. Turk Neurosurg 19:230-236.
19. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. 2001. Complex I and Parkinson's disease. IUBMB Life 52:135-141.
20. Grilli M, Pizzi M, Memo M, Spano P. 1996. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274:1383-1385.
21. Grootveld M, Halliwell B. 1986. Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Identification of hydroxylated derivatives of salicylate in human body fluids. Biochem J 237:499-504.
22. Halliwell B, Kaur H, Ingelman-Sundberg M. 1991. Hydroxylation of salicylate as an assay for hydroxyl radicals: A cautionary note. Free Rad Biol Med 10:439-441.
23. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK. 2007. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 64:576-580.
24. Hensley K, Pye QN, Maidt ML, Stewart CA, Robinson KA, Jaffrey F, Floyd RA. 1998. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 71:2549-2557.
25. Hernán MA, Logroscino G, García Rodríguez LA. 2006. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66:1097-1099.
26. Hissin PJ, Hilf R. 1976. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74:214-226.
27. Insel P. 1996. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill. p 617-657.
28. Jenner P. 1993. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146:6-13.
29. Karuppagounder SS, Madathil KS, Pandey M, Haobam R, Rajamma U, Mohanakumar KP. 2013. Quercetin up-regulates mitochondrial complex-I activity to protect against programed cell death in rotenone model of Parkinson's disease in rats. Neuroscience 236:136-148.
30. Kataoka M, Tonooka K, Ando T, Imai K, Aimoto T. 1997. Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory drugs. Free Radic Res 27:419-427.
31. L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B. 2010. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. J Neuroinflammation 7:83.
32. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Impagnatiello F, Marchetti B. 2011. Switching the microglial harmful phenotype promotes lifelong restoration of subtantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res 14:411-424.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with a Folin phenol reagent. J Biol Chem 193:265-275.
34. Madathil KS, Karuppagounder SS, Haobam R, Varghese M, Rajamma U, Mohanakumar KP. 2013. Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. Neurochem Int. http://dx.doi.org/10.1016/j.neuint.2013.01.007.
35. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, Daya S. 2004. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44:355-360.
36. Manthripragada AD, Schernhammer ES, Qiu J, Friis S, Wermuth L, Olsen JH, Ritz B. 2011. Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease. Neuroepidemiology 36:155-161.
37. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. 1995. Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem 64:1645-1654.
38. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. 1989. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163:1450-1455.
39. Mohanakumar KP, Hanbauer I, Chiueh CC. 1998. Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. J Chem Neuroanat 14:195-205.
40. Mohanakumar KP, Muralikrishnan D, Thomas B. 2000. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281-290.
41. Obata T. 2002. Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping. Toxicol Lett 132:83-93.
42. Patrono C. 1994. Aspirin as an antiplatelet drug. N Engl J Med 330:1287-1294.
43. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP. 2003. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966:245-252.
44. Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP. 2006. L-Deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 49:28-40.
45. Saravanan KS, Sindhu KM, Mohanakumar KP. 2005. Acute intra-nigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 1049:147-155.
46. Saravanan KS, Sindhu KM, Mohanakumar KP. 2007. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 42:247-253.
47. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269.
48. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. 2003. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179:9-16.
49. Siddiqui A, Mallajosyula JK, Rane A, Andersen JK. 2010. Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: Implications for early intervention on disease progression. Neurobiol Dis 40:444-448.
50. Sindhu KM, Saravanan KS, Mohanakumar KP. 2005. Behavioural differences in a rotenone-induced hemiparkinsonian rat model developed following intra-nigral or median forebrain bundle infusion. Brain Res 1051:25-34.
51. Sindhu KM, Banerjee R, Senthilkumar KS, Saravanan KS, China Raju B, Madhusudan Rao J, Mohanakumar KP. 2006. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 84:321-329.
52. Tasaki Y, Omura T, Yamada T, Ohkubo T, Suno M, Iida S, Sakaguchi T, Asari M, Shimizu K, Matsubara K. 2010. Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. Brain Res 1344:25-33.
53. Teismann P, Ferger B. 2001. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39:167-174.
54. Thomas B, Muralikrishnan D, Mohanakumar KP. 2000. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. Brain Res 852:221-224.
55. Thomas B, Saravanan KS, Mohanakumar KP. 2008. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem Int 52:990-1001.
56. Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H. 2006. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 21:964-969.
57. van der Merwe JA, Dubery IA. 2006. Benzothiadiazole inhibits mitochondrial NADH:Ubiquinone oxidoreductase in tobacco. J Plant Physiol 163:877-882.
58. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. 2007. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69:1836-1842.
59. Weissmann G. 1991. Aspirin. Sci Am 264:84-90.
60. Yoon H, Lee GH, Kim DS, Kim KW, Kim HR, Chae HJ. 2011. The effects of 3, 4 or 5 amino salicylic acids on manganese-induced neuronal death: ER stress and mitochondrial complexes. Toxicol In Vitro 25:1259-1268.